Viveve Medical (NASDAQ:VIVE)‘s stock had its “hold” rating reiterated by investment analysts at Maxim Group in a report issued on Friday, AnalystRatings.com reports.
The analysts wrote, “Yesterday, after the Market close, VIVE reported 2Q19 revenue inline with our estimates adjusted for the preannouncement on July 22, 2019, but lower than consensus.””
VIVE has been the subject of several other reports. Mizuho downgraded Viveve Medical from a “buy” rating to an “underperform” rating and lowered their price objective for the stock from $4.00 to $0.20 in a research note on Tuesday, July 23rd. LADENBURG THALM/SH SH downgraded Viveve Medical from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 24th. Raymond James downgraded Viveve Medical from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 23rd. Finally, Stifel Nicolaus downgraded Viveve Medical from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $3.00 to $1.00 in a research note on Monday, July 22nd. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $2.24.
Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The firm had revenue of $3.01 million during the quarter, compared to the consensus estimate of $2.98 million. Viveve Medical had a negative return on equity of 2,979.48% and a negative net margin of 265.51%. As a group, analysts anticipate that Viveve Medical will post -0.74 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in VIVE. Accredited Investors Inc. bought a new position in Viveve Medical during the first quarter valued at $31,000. Bank of New York Mellon Corp boosted its holdings in shares of Viveve Medical by 266.6% in the fourth quarter. Bank of New York Mellon Corp now owns 45,223 shares of the company’s stock worth $47,000 after acquiring an additional 32,888 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Viveve Medical by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 216,566 shares of the company’s stock worth $227,000 after acquiring an additional 25,975 shares during the period. Meitav Dash Investments Ltd. boosted its holdings in shares of Viveve Medical by 30.1% in the first quarter. Meitav Dash Investments Ltd. now owns 988,573 shares of the company’s stock worth $955,000 after acquiring an additional 228,517 shares during the period. Finally, Pennsylvania Trust Co boosted its holdings in shares of Viveve Medical by 212.3% in the first quarter. Pennsylvania Trust Co now owns 42,154 shares of the company’s stock worth $7,681,000 after acquiring an additional 28,654 shares during the period. 59.73% of the stock is owned by institutional investors and hedge funds.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.
Featured Article: How is a management fee different from a performance fee?
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.